Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ARMP 
Armata Pharmaceuticals Inc (ARMP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: ARMP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.86% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 108.33M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 1 | Beta 1.1 | 52 Weeks Range 0.90 - 3.14 | Updated Date 09/15/2025 |
52 Weeks Range 0.90 - 3.14 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -315.54% |
Management Effectiveness
Return on Assets (TTM) -23.35% | Return on Equity (TTM) -3439.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 246142735 | Price to Sales(TTM) 15.77 |
Enterprise Value 246142735 | Price to Sales(TTM) 15.77 | ||
Enterprise Value to Revenue 148.14 | Enterprise Value to EBITDA 15.72 | Shares Outstanding 36229800 | Shares Floating 10874749 |
Shares Outstanding 36229800 | Shares Floating 10874749 | ||
Percent Insiders 69.48 | Percent Institutions 2.02 |
Upturn AI SWOT
Armata Pharmaceuticals Inc
Company Overview
History and Background
Armata Pharmaceuticals, Inc. (formerly AmpliPhi Biosciences) is a biotechnology company focused on developing and commercializing phage-based therapies to treat antibiotic-resistant infections. Founded to address the growing threat of antimicrobial resistance, the company has evolved through preclinical and clinical development stages.
Core Business Areas
- Phage-Based Therapeutics Development: Armata's core business is developing and commercializing bacteriophage therapies targeting antibiotic-resistant bacterial infections. This includes research, preclinical studies, clinical trials, and manufacturing of phage-based products.
- Bacteriophage Library and Screening: Maintaining and expanding a diverse library of bacteriophages, along with screening capabilities, allows for identification and development of new therapeutic candidates.
Leadership and Structure
Armata's leadership team includes individuals with experience in biotechnology, pharmaceuticals, and infectious diseases. The organizational structure is typical of a small, clinical-stage biotech company, with departments focused on research, development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- RAB-1: RAB-1 is a proprietary bacteriophage cocktail targeting Pseudomonas aeruginosa infections, particularly in cystic fibrosis patients. Armata is pursuing clinical trials and regulatory approvals. Competitors include traditional antibiotics and other companies developing novel anti-infectives.
- AP-PA02: AP-PA02 is another investigational phage therapy targeting Pseudomonas aeruginosa. Market share is currently non-existent as this is a treatment being developed, but the potential market for addressing Pseudomonas infections is significant. Competitors include traditional antibiotics and other companies developing novel anti-infectives
Market Dynamics
Industry Overview
The industry is focused on developing novel anti-infectives to combat antibiotic resistance. This includes research into new antibiotics, phage therapies, and other alternative approaches.
Positioning
Armata is positioned as a leader in the development of phage therapies to combat antibiotic-resistant infections. Its competitive advantage lies in its proprietary phage library and expertise in phage-based drug development.
Total Addressable Market (TAM)
The TAM for antibiotic-resistant infections is estimated to be billions of dollars annually. Armata is positioned to capture a share of this market by providing alternative therapeutic options. Actual market size is dependent on the regulatory landscape.
Upturn SWOT Analysis
Strengths
- Proprietary phage library
- Expertise in phage therapy development
- Potential for personalized medicine approach
- Addressing a critical unmet medical need
Weaknesses
- Clinical stage company with no approved products
- Reliance on successful clinical trial outcomes
- Uncertain regulatory pathway for phage therapies
- Limited financial resources
Opportunities
- Growing demand for alternative anti-infectives
- Potential for strategic partnerships with pharmaceutical companies
- Expanding applications of phage therapy to other diseases
- Favorable regulatory changes
Threats
- Competition from traditional antibiotics and other novel anti-infectives
- Clinical trial failures
- Regulatory hurdles
- Manufacturing challenges
Competitors and Market Share
Key Competitors
- MRK
- LLY
- ABBV
Competitive Landscape
Armata faces competition from established pharmaceutical companies and other biotech companies developing novel anti-infectives. Its advantage lies in its phage therapy expertise.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's development stage. Growth is dependent on clinical trial success and regulatory approvals.
Future Projections: Future growth is projected based on analyst estimates and expectations for commercialization of phage therapies.
Recent Initiatives: Recent initiatives include advancing clinical trials for RAB-1, expanding its phage library, and seeking strategic partnerships.
Summary
Armata Pharmaceuticals is a high-risk, high-reward clinical-stage company focused on developing phage therapies to combat antibiotic resistance. Its core strength lies in its phage library and expertise, however regulatory hurdles and clinical trial risks remain substantial. Success depends on positive clinical trial outcomes and gaining regulatory approval, which could open significant opportunities in a growing market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Company website
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. The company's future performance is uncertain and subject to various risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Armata Pharmaceuticals Inc
Exchange NYSE MKT | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2011-03-09 | CEO & Director Dr. Deborah L. Birx M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 60 | Website https://www.armatapharma.com |
Full time employees 60 | Website https://www.armatapharma.com | ||
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.